Satellos Bioscience (MSLE) Accounts Payables (2023 - 2026)

Satellos Bioscience (MSLE) has 4 years of Accounts Payables data on file, last reported at $4.6 million in Q1 2026.

• On a quarterly basis, Accounts Payables changed N/A year-over-year to $4.6 million in Q1 2026; TTM through Mar 2026 was $4.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $4.1 million, up 14.57% from the prior year.
• Accounts Payables for Q1 2026 stood at $4.6 million, up from $4.1 million in the prior quarter.
• Over the last five years, Accounts Payables for MSLE reached as high as $4.6 million in Q1 2026 and fell as low as $2.7 million in Q4 2023.
• Historically, Accounts Payables has averaged $3.8 million across 4 years, with a median of $3.9 million in 2024.
• Across the five-year window, Accounts Payables surged 38.63% in 2024 and gained 11.24% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $2.7 million in 2023, then surged by 38.63% to $3.7 million in 2024, then climbed by 11.24% to $4.1 million in 2025, then increased by 11.16% to $4.6 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $4.6 million in Q1 2026, $4.1 million in Q4 2025, and $3.7 million in Q4 2024.